Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis
To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis. Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single tr...
Gespeichert in:
Veröffentlicht in: | Investigative ophthalmology & visual science 2013-07, Vol.54 (7), p.4864-4870 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4870 |
---|---|
container_issue | 7 |
container_start_page | 4864 |
container_title | Investigative ophthalmology & visual science |
container_volume | 54 |
creator | Lightman, Susan Belfort, Jr, Rubens Naik, Rupali K Lowder, Careen Foster, C Stephen Rentz, Anne M Cui, Harry Whitcup, Scott M Kowalski, Jonathan W Revicki, Dennis A |
description | To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis.
Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with DEX implant 0.70 mg (n=77), DEX implant 0.35 mg (n=76), or a sham procedure (n=76) and followed for 26 weeks. Vision-related functioning was measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) assessed at baseline and at weeks 8, 16, and 26 or early exit. Analysis of covariance and mixed model analysis of covariance were used to compare vision-related functioning between the DEX implant 0.70 and 0.35 mg groups and the sham group.
By 8 weeks, the DEX implant 0.70 mg group demonstrated significant improvements in NEI VFQ-25 subscales near vision (P=0.031), distance vision (P=0.023), peripheral vision (P=0.045), vision-specific social functioning (P=0.019), and the NEI VFQ-25 composite score (P=0.007) compared with sham. After 26 weeks, the DEX implant 0.70 mg group reported significant improvements in NEI VFQ-25 subscales distance vision (P=0.003), vision-specific role difficulties (P=0.038), vision-specific dependency (P=0.017), vision-specific social functioning (P=0.009), vision-specific mental health (P=0.036), and the composite score (P=0.001) compared with sham.
In patients with noninfectious intermediate or posterior uveitis receiving a single treatment of DEX implant 0.70 mg, significant and clinically meaningful improvements in patient-reported visual functioning were observed as early as week 8 and were maintained over 26 weeks. (ClinicalTrials.gov number, NCT00333814.). |
doi_str_mv | 10.1167/iovs.12-10981 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1411628425</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1411628425</sourcerecordid><originalsourceid>FETCH-LOGICAL-c332t-8a879f9e8e992bbe4ccbaf54caf046091441b191da6f291b9983e17b5e4ec1b83</originalsourceid><addsrcrecordid>eNpNkD1PwzAQhi0EolAYWZFHlhSfkzT2iCq-pEoswBo57hmMkrjYTgUSPx6HFsTk06vHr-4eQs6AzQDm1aV1mzADngGTAvbIEZQlz8pK5Pv_5gk5DuGNMQ7A2SGZ8LyaAxPVEfl6tsG6PvPYqograoZexxTY_oW6IWrXYaDO0BV-qA7jqwquR2r76NXGRo-qpbZbt6qPKaT9-NHg2DCEkULf4cqmZuo8XbuQApumYYM22nBCDoxqA57u3il5url-XNxly4fb-8XVMtN5zmMmlKikkShQSt40WGjdKFMWWhlWzJmEooAGJKzU3HAJjZQiR6iaEgvU0Ih8Si62vWvv3gcMse5s0NimtTEtWkORVHJR8DKh2RbV3oXg0dRrbzvlP2tg9Si8HoXXwOsf4Yk_31UPTTr1j_41nH8D7TSA-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1411628425</pqid></control><display><type>article</type><title>Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lightman, Susan ; Belfort, Jr, Rubens ; Naik, Rupali K ; Lowder, Careen ; Foster, C Stephen ; Rentz, Anne M ; Cui, Harry ; Whitcup, Scott M ; Kowalski, Jonathan W ; Revicki, Dennis A</creator><creatorcontrib>Lightman, Susan ; Belfort, Jr, Rubens ; Naik, Rupali K ; Lowder, Careen ; Foster, C Stephen ; Rentz, Anne M ; Cui, Harry ; Whitcup, Scott M ; Kowalski, Jonathan W ; Revicki, Dennis A</creatorcontrib><description>To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis.
Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with DEX implant 0.70 mg (n=77), DEX implant 0.35 mg (n=76), or a sham procedure (n=76) and followed for 26 weeks. Vision-related functioning was measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) assessed at baseline and at weeks 8, 16, and 26 or early exit. Analysis of covariance and mixed model analysis of covariance were used to compare vision-related functioning between the DEX implant 0.70 and 0.35 mg groups and the sham group.
By 8 weeks, the DEX implant 0.70 mg group demonstrated significant improvements in NEI VFQ-25 subscales near vision (P=0.031), distance vision (P=0.023), peripheral vision (P=0.045), vision-specific social functioning (P=0.019), and the NEI VFQ-25 composite score (P=0.007) compared with sham. After 26 weeks, the DEX implant 0.70 mg group reported significant improvements in NEI VFQ-25 subscales distance vision (P=0.003), vision-specific role difficulties (P=0.038), vision-specific dependency (P=0.017), vision-specific social functioning (P=0.009), vision-specific mental health (P=0.036), and the composite score (P=0.001) compared with sham.
In patients with noninfectious intermediate or posterior uveitis receiving a single treatment of DEX implant 0.70 mg, significant and clinically meaningful improvements in patient-reported visual functioning were observed as early as week 8 and were maintained over 26 weeks. (ClinicalTrials.gov number, NCT00333814.).</description><identifier>ISSN: 1552-5783</identifier><identifier>EISSN: 1552-5783</identifier><identifier>DOI: 10.1167/iovs.12-10981</identifier><identifier>PMID: 23761087</identifier><language>eng</language><publisher>United States</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Anti-Inflammatory Agents - administration & dosage ; Dexamethasone - administration & dosage ; Drug Implants ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Surveys and Questionnaires ; Uveitis, Posterior - drug therapy ; Uveitis, Posterior - physiopathology ; Visual Acuity - physiology ; Young Adult</subject><ispartof>Investigative ophthalmology & visual science, 2013-07, Vol.54 (7), p.4864-4870</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c332t-8a879f9e8e992bbe4ccbaf54caf046091441b191da6f291b9983e17b5e4ec1b83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23761087$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lightman, Susan</creatorcontrib><creatorcontrib>Belfort, Jr, Rubens</creatorcontrib><creatorcontrib>Naik, Rupali K</creatorcontrib><creatorcontrib>Lowder, Careen</creatorcontrib><creatorcontrib>Foster, C Stephen</creatorcontrib><creatorcontrib>Rentz, Anne M</creatorcontrib><creatorcontrib>Cui, Harry</creatorcontrib><creatorcontrib>Whitcup, Scott M</creatorcontrib><creatorcontrib>Kowalski, Jonathan W</creatorcontrib><creatorcontrib>Revicki, Dennis A</creatorcontrib><title>Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis</title><title>Investigative ophthalmology & visual science</title><addtitle>Invest Ophthalmol Vis Sci</addtitle><description>To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis.
Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with DEX implant 0.70 mg (n=77), DEX implant 0.35 mg (n=76), or a sham procedure (n=76) and followed for 26 weeks. Vision-related functioning was measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) assessed at baseline and at weeks 8, 16, and 26 or early exit. Analysis of covariance and mixed model analysis of covariance were used to compare vision-related functioning between the DEX implant 0.70 and 0.35 mg groups and the sham group.
By 8 weeks, the DEX implant 0.70 mg group demonstrated significant improvements in NEI VFQ-25 subscales near vision (P=0.031), distance vision (P=0.023), peripheral vision (P=0.045), vision-specific social functioning (P=0.019), and the NEI VFQ-25 composite score (P=0.007) compared with sham. After 26 weeks, the DEX implant 0.70 mg group reported significant improvements in NEI VFQ-25 subscales distance vision (P=0.003), vision-specific role difficulties (P=0.038), vision-specific dependency (P=0.017), vision-specific social functioning (P=0.009), vision-specific mental health (P=0.036), and the composite score (P=0.001) compared with sham.
In patients with noninfectious intermediate or posterior uveitis receiving a single treatment of DEX implant 0.70 mg, significant and clinically meaningful improvements in patient-reported visual functioning were observed as early as week 8 and were maintained over 26 weeks. (ClinicalTrials.gov number, NCT00333814.).</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Dexamethasone - administration & dosage</subject><subject>Drug Implants</subject><subject>Female</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Surveys and Questionnaires</subject><subject>Uveitis, Posterior - drug therapy</subject><subject>Uveitis, Posterior - physiopathology</subject><subject>Visual Acuity - physiology</subject><subject>Young Adult</subject><issn>1552-5783</issn><issn>1552-5783</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkD1PwzAQhi0EolAYWZFHlhSfkzT2iCq-pEoswBo57hmMkrjYTgUSPx6HFsTk06vHr-4eQs6AzQDm1aV1mzADngGTAvbIEZQlz8pK5Pv_5gk5DuGNMQ7A2SGZ8LyaAxPVEfl6tsG6PvPYqograoZexxTY_oW6IWrXYaDO0BV-qA7jqwquR2r76NXGRo-qpbZbt6qPKaT9-NHg2DCEkULf4cqmZuo8XbuQApumYYM22nBCDoxqA57u3il5url-XNxly4fb-8XVMtN5zmMmlKikkShQSt40WGjdKFMWWhlWzJmEooAGJKzU3HAJjZQiR6iaEgvU0Ih8Si62vWvv3gcMse5s0NimtTEtWkORVHJR8DKh2RbV3oXg0dRrbzvlP2tg9Si8HoXXwOsf4Yk_31UPTTr1j_41nH8D7TSA-g</recordid><startdate>20130718</startdate><enddate>20130718</enddate><creator>Lightman, Susan</creator><creator>Belfort, Jr, Rubens</creator><creator>Naik, Rupali K</creator><creator>Lowder, Careen</creator><creator>Foster, C Stephen</creator><creator>Rentz, Anne M</creator><creator>Cui, Harry</creator><creator>Whitcup, Scott M</creator><creator>Kowalski, Jonathan W</creator><creator>Revicki, Dennis A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130718</creationdate><title>Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis</title><author>Lightman, Susan ; Belfort, Jr, Rubens ; Naik, Rupali K ; Lowder, Careen ; Foster, C Stephen ; Rentz, Anne M ; Cui, Harry ; Whitcup, Scott M ; Kowalski, Jonathan W ; Revicki, Dennis A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c332t-8a879f9e8e992bbe4ccbaf54caf046091441b191da6f291b9983e17b5e4ec1b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Dexamethasone - administration & dosage</topic><topic>Drug Implants</topic><topic>Female</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Surveys and Questionnaires</topic><topic>Uveitis, Posterior - drug therapy</topic><topic>Uveitis, Posterior - physiopathology</topic><topic>Visual Acuity - physiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lightman, Susan</creatorcontrib><creatorcontrib>Belfort, Jr, Rubens</creatorcontrib><creatorcontrib>Naik, Rupali K</creatorcontrib><creatorcontrib>Lowder, Careen</creatorcontrib><creatorcontrib>Foster, C Stephen</creatorcontrib><creatorcontrib>Rentz, Anne M</creatorcontrib><creatorcontrib>Cui, Harry</creatorcontrib><creatorcontrib>Whitcup, Scott M</creatorcontrib><creatorcontrib>Kowalski, Jonathan W</creatorcontrib><creatorcontrib>Revicki, Dennis A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Investigative ophthalmology & visual science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lightman, Susan</au><au>Belfort, Jr, Rubens</au><au>Naik, Rupali K</au><au>Lowder, Careen</au><au>Foster, C Stephen</au><au>Rentz, Anne M</au><au>Cui, Harry</au><au>Whitcup, Scott M</au><au>Kowalski, Jonathan W</au><au>Revicki, Dennis A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis</atitle><jtitle>Investigative ophthalmology & visual science</jtitle><addtitle>Invest Ophthalmol Vis Sci</addtitle><date>2013-07-18</date><risdate>2013</risdate><volume>54</volume><issue>7</issue><spage>4864</spage><epage>4870</epage><pages>4864-4870</pages><issn>1552-5783</issn><eissn>1552-5783</eissn><abstract>To evaluate the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in patients with noninfectious intermediate or posterior uveitis.
Patient eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with DEX implant 0.70 mg (n=77), DEX implant 0.35 mg (n=76), or a sham procedure (n=76) and followed for 26 weeks. Vision-related functioning was measured using the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) assessed at baseline and at weeks 8, 16, and 26 or early exit. Analysis of covariance and mixed model analysis of covariance were used to compare vision-related functioning between the DEX implant 0.70 and 0.35 mg groups and the sham group.
By 8 weeks, the DEX implant 0.70 mg group demonstrated significant improvements in NEI VFQ-25 subscales near vision (P=0.031), distance vision (P=0.023), peripheral vision (P=0.045), vision-specific social functioning (P=0.019), and the NEI VFQ-25 composite score (P=0.007) compared with sham. After 26 weeks, the DEX implant 0.70 mg group reported significant improvements in NEI VFQ-25 subscales distance vision (P=0.003), vision-specific role difficulties (P=0.038), vision-specific dependency (P=0.017), vision-specific social functioning (P=0.009), vision-specific mental health (P=0.036), and the composite score (P=0.001) compared with sham.
In patients with noninfectious intermediate or posterior uveitis receiving a single treatment of DEX implant 0.70 mg, significant and clinically meaningful improvements in patient-reported visual functioning were observed as early as week 8 and were maintained over 26 weeks. (ClinicalTrials.gov number, NCT00333814.).</abstract><cop>United States</cop><pmid>23761087</pmid><doi>10.1167/iovs.12-10981</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1552-5783 |
ispartof | Investigative ophthalmology & visual science, 2013-07, Vol.54 (7), p.4864-4870 |
issn | 1552-5783 1552-5783 |
language | eng |
recordid | cdi_proquest_miscellaneous_1411628425 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adolescent Adult Aged Aged, 80 and over Analysis of Variance Anti-Inflammatory Agents - administration & dosage Dexamethasone - administration & dosage Drug Implants Female Humans Intravitreal Injections Male Middle Aged Surveys and Questionnaires Uveitis, Posterior - drug therapy Uveitis, Posterior - physiopathology Visual Acuity - physiology Young Adult |
title | Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A58%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vision-related%20functioning%20outcomes%20of%20dexamethasone%20intravitreal%20implant%20in%20noninfectious%20intermediate%20or%20posterior%20uveitis&rft.jtitle=Investigative%20ophthalmology%20&%20visual%20science&rft.au=Lightman,%20Susan&rft.date=2013-07-18&rft.volume=54&rft.issue=7&rft.spage=4864&rft.epage=4870&rft.pages=4864-4870&rft.issn=1552-5783&rft.eissn=1552-5783&rft_id=info:doi/10.1167/iovs.12-10981&rft_dat=%3Cproquest_cross%3E1411628425%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1411628425&rft_id=info:pmid/23761087&rfr_iscdi=true |